Mayo Clinic researchers to present XOMA 052 data at 101st AACR Annual Meeting

Editorial Checklist Reviewed
Apr 9 2010NewsGuard 100/100 Score

XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that researchers from the Mayo Clinic will be presenting data on the use of XOMA's high-affinity antibody to interleukin-1 beta (IL-1 beta), XOMA 052, in myeloma at the 101st Annual Meeting of the American Association of Cancer Research (AACR).

The poster, entitled "A novel humanized anti-IL-1beta antibody is highly effective at inhibiting IL-1 induced IL-6 production in myeloma patients in vitro" will be presented on Monday, April 19 at 2:00 PM Eastern. The abstract upon which the poster is based is now available on the conference Web site: www.aacr.org.

Source:

http://www.xoma.com/

Posted in: Drug Trial News | Medical Science News | Medical Condition News

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Maternal antibodies may hinder malaria vaccine effectiveness in infants
Researchers develop new antibody with potential to treat several types of cancer
New antibody platform targets evolving viruses
Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR
Novel antibodies show promise for tumor targeting and RAD51 inhibition
Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024
Elevated antibody responses to Epstein-Barr virus linked to increased risk of multiple sclerosis
Clinical trial highlights efficacy of imlifidase for kidney transplant recipients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Maternal RSV vaccination timing optimizes newborn immunity through improved antibody transfer